Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019027670) VACCINES AGAINST TICK-BORNE DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/027670 International Application No.: PCT/US2018/042496
Publication Date: 07.02.2019 International Filing Date: 17.07.2018
IPC:
A61K 39/00 (2006.01) ,A61K 39/02 (2006.01) ,A61K 39/39 (2006.01) ,A61K 47/06 (2006.01) ,A61P 31/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
Applicants:
KANSAS STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; 2005 Research Park Circle, Suite 105 Manhattan, KS 66502, US
Inventors:
GANTA, Roman, R.; US
Agent:
TRUITT, Tracey, S.; US
ALLEN, Derick E.; US
AMODIO, Lucas M.; US
ATKINS, Bruce T.; US
BEULICK, John S.; US
BLOCK, Zachary J.; US
BRACCIANO, Daniel D.; US
BRENNAN, Patrick E.; US
BROPHY, Richard L.; US
BUTLER, Christopher H.; US
COYLE, Patrick J.; US
FITZGERALD, Daniel M.; US
FLOREK, Erin M.; US
GOFF, Christopher M.; US
HARPER, James D.; US
HARPER, Jesse S.; US
HEINEN JR., James M.; US
HENSON, James W.; US
HILMERT, Laura J.; US
HOEKEL, Jennifer E.; US
INACAY, Brian D.; US
KEPPEL, Nicholas A.; US
KU, Deborah S.; US
LONGMEYER, Michael H.; US
MCCAY, Michael G.; US
MOLLER-JACOBS, Rose L.; US
MUELLER, Jacob R.; US
MUNSELL, Michael G.; US
POLAND, Eric G.; US
RASCHE, Patrick W.; US
REESER III, Robert B.; US
SCHNEIDERJOHN, Robert L.; US
SCHNIEDERS, Kelley A.; US
SCHUTH, Richard A.; US
SLATER, Brian T.; US
SMELCER, Paul L.; US
SNIDER, Josh C.; US
SOOTER, Miranda M.; US
THOMAS, Mark A.; US
VANDER MOLEN, Michael J.; US
VANDER TUIG, Marc W.; US
VANENGELEN, Catherine E.; US
VANVLIET, David S.; US
WULLER, Adam R.; US
ZEE-CHENG, Brendan R.; US
ZYCHLEWICZ, William J.; US
Priority Data:
62/533,55031.07.2017US
Title (EN) VACCINES AGAINST TICK-BORNE DISEASES
(FR) VACCINS CONTRE DES MALADIES TRANSMISES PAR LES TIQUES
Abstract:
(EN) The present disclosure provides immunogenic compositions and vaccines effective for reducing the incidence of or severity of clinical signs or symptoms of infection by a tick-bome pathogen selected from the group consisting of Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, and Anaplasma phagocytophilum. In preferred forms, the immunogenic composition comprises an inactivated whole cell bacteria selected from the group consisting of Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, Anaplasma phagocytophilum, and any combination thereof, together with an adjuvant.
(FR) La présente invention concerne des compositions immunogènes et des vaccins efficaces pour réduire l'incidence ou la gravité des signes cliniques ou des symptômes d'une infection par un agent pathogène transmis par les tiques, appartenant au groupe constitué par Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, et Anaplasma phagocytophilum. Dans des formes préférées, la composition immunogène comprend une bactérie cellulaire entière inactivée sélectionnée dans le groupe constitué par Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, Anaplasma phagocytophilum, et toute combinaison de ceux-ci, conjointement avec un adjuvant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)